AI Article Synopsis
- Researchers examined potential hearing loss in newborns born to mothers treated with antimalarial drugs during pregnancy, to understand the effects of these drugs on the newborn's auditory system.
- The study included a cohort of 527 newborns, comparing 32 exposed to antimalarials with 495 not exposed, with data collected from various medical records and interviews.
- Findings indicated that the majority of newborns from the exposed group passed initial hearing screenings, suggesting that antimalarial drug exposure did not significantly affect their hearing.
Article Abstract
Introduction: Studies have demonstrated the ototoxic effects of antimalarial drugs in individuals who receive these drugs, but little is known regarding the toxicity of these drugs in the newborn auditory system when administered to the mother receive the drug during pregnancy.
Objective: To verify the incidence of hearing loss in neonates who have no other associated risk indicators, born to mothers treated for malaria during pregnancy.
Methods: A retrospective, quantitative cohort study was developed at Hospital de Base Dr. Ary Pinheiro and Clínica Limiar, both located in the municipality of Porto Velho (Rondônia). The sample consisted of 527 newborns divided into two groups: exposed to antimalarials drugs during pregnancy group (n = 32) and non-exposed group (n = 495). Data collection took place from September 2014 to December 2015, through an interview with the mothers and/or guardians of the newborn, through the newborns' and the mothers' records, and the neonatal hearing screening database of the above-mentioned institutions.
Results: All the neonates in the exposed group, assessed through the recording of transient otoacoustic emissions associated with the automated brainstem auditory evoked potential test, underwent neonatal hearing screening in the first examination. Among the newborns in the non-exposed group, 30 showed failure and were retested. Of these, one continued to fail and was referred for diagnosis, in whom the results showed to be within the normal range. Among the neonates of the exposed group, infection with Plasmodium vivax was the most frequent, and was similarly distributed among the gestational trimesters, and chloroquine was the most commonly used antimalarial drug treatment more often given during the third trimester; these findings did not show any influence on the audiological findings of the studied neonates.
Conclusion: The present study did not identify any cases of hearing loss in neonates born to mothers who used antimalarial drugs during gestation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422607 | PMC |
| http://dx.doi.org/10.1016/j.bjorl.2019.06.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Auditory brainstem response thresholds and functional hearing: implications for cochlear implant candidacy.
Int J Audiol
December 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Antwerp University Hospital (UZA), Edegem, Belgium.
Objective: This study assessed the relevance of auditory brainstem response (ABR) thresholds in evaluating cochlear implantation (CI) candidacy by studying their correlation with functional hearing in patients with sensorineural hearing loss (SNHL).
Design And Study Sample: In this retrospective study, we examined correlations between ABR thresholds, speech perception scores in quiet and pure-tone audiometry in 191 adults. We compared these correlations between individuals with different degrees of SNHL to discern differences in potential CI candidates and individual with less severe SNHL.
Hearing aid adoption rates among adults without hearing aid experience in an audiology clinic before and after price unbundling.
Int J Audiol
December 2024
Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
Objectives: The purpose of this study was to investigate a policy-related factor and patient-related factors that might affect hearing aid adoption for adults, specifically price unbundling, and demographic and audiologic factors, respectively.
Design: Retrospective data from hearing aid consultation appointments in an audiology clinic in a medical centre were examined. Appointments were conducted between 2019 and 2023, capturing visits when services and devices were charged using a model that was bundled (2019-2022) and unbundled (2023).
Unlabelled: Auditory masking-the interference of the encoding and processing of an acoustic stimulus imposed by one or more competing stimuli-is nearly omnipresent in daily life, and presents a critical barrier to many listeners, including people with hearing loss, users of hearing aids and cochlear implants, and people with auditory processing disorders. The perceptual aspects of masking have been actively studied for several decades, and particular emphasis has been placed on masking of speech by other speech sounds. The neural effects of such masking, especially at the subcortical level, have been much less studied, in large part due to the technical limitations of making such measurements.
View Article and Find Full Text PDFObjectives: Auditory brainstem response (ABR) is the gold standard to assess hearing loss in pediatric patients. Multiple widely accepted ABR protocols with varying parameters are accepted, difference in standards may lead to misdiagnosis or delay in diagnosis and treatment. This study investigates the quality of ABR testing in pediatric patients in addition to changes in diagnoses and management.
View Article and Find Full Text PDFAuditory and Speech Outcomes Following Transcutaneous Bone Conduction Hearing Implantation.
Cureus
November 2024
Otolaryngology- Head and Neck Surgery, King Abdulaziz University Faculty of Medicine, Jeddah, SAU.
Objectives: Implantable bone conduction hearing devices offer excellent auditory rehabilitation. Transcutaneous devices, which use an implanted magnet, are gaining popularity due to higher skin complications associated with traditional percutaneous devices. The Cochlear Baha® Attract System (Cochlear Corporation, Sydney, Australia) is a transcutaneous device and is regarded as a passive transcutaneous implant.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!